CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

How Can We Achieve the Fastest Therapeutic Response for Migraine? CME
Chairperson: David Dodick, MD, FRCP (C), FACP; Faculty: Rami Burstein, PhD; Robert Kaniecki, MD; Reijo Salonen, MD, PhD; James Adelman, MD, FAAN, FACP, FASH
Disclosures

Release Date: March 11, 2004; Valid for credit through March 11, 2005

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "How Can We Achieve the Fastest Therapeutic Response for Migraine?" satellite symposium held at the Marriott's Camelback Inn, Resort, Golf Club and Spa in Scottsdale, Arizona on November 14, 2003.

Contents of This CME Activity
This program is offered in two formats. Please choose one of the versions:

    Flash Version
    (A multimedia presentation with synchronized audio, slides and transcript.)
    Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version.
    Download the Macromedia Flash Player 5 plug-In:

    Get Flash 5

    --OR--

    Slides with transcript and RealAudio:

  1. Central Sensitization: Implications for Diagnosis and Treatment
    by Rami Burstein, PhD
    Presentation Summary

  2. Using Migraine Symptom Presentation to Guide Therapy: What Pain in the Neck Teaches Us About Pain in the Head
    by Robert Kaniecki, MD
    Neck Pain in Acute Migraine
    Neck Pain and Triptan Response
    A Prospective Study of Migraineurs With Neck Pain: Study Design
    Early Intervention in the Prospective Study of Migraineurs With Neck Pain
    Later Intervention in the Prospective Study of Migraineurs With Neck Pain
    Insights From the Study
    Presentation Summary

  3. Engineering Novel Triptan Formulations: An R&D Perspective
    by Reijo Salonen, MD, PhD
    The Rationale for Novel Triptan Formulations
    Pharmacokinetic Profiles: Rapid-Release and Conventional Tablets
    Additional Findings From the Pharmacokinetic Profile Study
    Pharmacokinetic Profile Summary
    Presentation Summary

  4. Practical Use of Newer Oral Triptan Formulations
    by James Adelman, MD
    Double-Blind, Placebo-Controlled Study of Sumatriptan Rapid-Release Tablets: Study Background
    Double-Blind, Placebo-Controlled Study of Sumatriptan Rapid-Release Tablets: Study Findings
    Sumatriptan Rapid-Release Tablets: Study Summary
    Presentation Summary

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape, Scienta Healthcare Education®, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2004 Scienta Healthcare Education®.
Glaxo Smith Kline
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
 
Scienta
Scienta Healthcare Educationý is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Scienta Healthcare Education® designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.